Home News

Biocon tumbles 3% on 5 USFDA observations for Bengaluru unit
Monday, January 27, 2020, 7:44 PM
Shares of Biocon lost 2.8 percent intraday on January 27 after receiving five observations from the US health regulator for Bengaluru unit. The pharma company informed exchanges that the US FDA conducted a PAI and GMP inspection of the API manufacturing facility. It further said it would respond to the FDA with a CAPA and was confident of addressing these observations expeditiously.

Get FREE Credit Score now!
Attention!
This is to inform that Suvision Holdings Pvt Ltd ("IndianMoney.com") do not charge any fees/security deposit/advances towards outsourcing any of its activities. All stake holders are cautioned against any such fraud.